4-hydroxy-2-nonenal and Prostatic-Hyperplasia

4-hydroxy-2-nonenal has been researched along with Prostatic-Hyperplasia* in 1 studies

Other Studies

1 other study(ies) available for 4-hydroxy-2-nonenal and Prostatic-Hyperplasia

ArticleYear
[Expressions of glutathione S-transferase P1 and 4- hydroxynonenal and the progression of prostate cancer].
    Zhonghua nan ke xue = National journal of andrology, 2017, Volume: 23, Issue:5

    To investigate the expressions of glutathione S-transferase (GSTP1) and tetra-hydroxynonenal (4-HNE) in prostate cancer (PCa) and their clinical significance.. We determined the expressions of GSTP1 and 4-HNE in 40 patients with PCa and another 42 with benign prostatic hyperplasia (BPH) by immunohistochemistry and analyzed their relationship with Gleason grades.. The expression rate of GSTP1 was 92.9% in the BPH tissue, and those in the highly, moderately, and lowly differentiated PCa tissues were 58.3%, 20.0%, and 16.7%, respectively, significantly higher in the BPH than in the PCa group (P <0.01). However, the positive rate of 4-HNE was only 5.0% in the BPH tissue, markedly lower than 91.6%, 100.0%, and 100.0% in the highly, moderately, and lowly differentiated PCa tissues (P <0.01). There was a negative correlation between the expression of GSTP1 and that of 4-HNE in the PCa tissue (r = -2.73, P <0.01).. Expression deletion of GSTP1 and high expression of 4-HNE may play an important role in the progression of prostate cancer.. 目的: 探讨谷胱甘肽S转移酶P1(GSTP1)和四羟基壬烯(4-HNE)在前列腺癌组织中的表达及其临床意义。方法: 采用免疫组化方法检测40例前列腺癌组织及42例BPH组织中GSTP1和4-HNE 的表达,分析GSTP1和4-HNE的表达与Gleason分级之间的关系。结果: GSTP1在BPH组织中为高表达(92.9%),40例前列腺癌组织中GSTP1表达率在高、中、低分化癌中分别为58.3%、20.0%、16.7%,呈下降趋势,两组GSTP1表达差异有统计学意义(P<0.01)。4-HNE在前列腺增生组织中阳性表达率较低,仅为5.0%。40例前列腺癌组织中4-HNE高表达,在高、中、低分化癌中分别为91.6%、100.0%、100.0%,呈明显上升趋势,两组4-HNE表达差异有统计学意义(P<0.01)。前列腺癌组织中GSTP1和4-HNE阳性表达呈负相关(r=-2.73,P<0.01)。结论: GSTP1表达缺失和4-HNE的高表达,可能在前列腺癌的进展中起重要作用。.

    Topics: Aldehydes; Disease Progression; Glutathione S-Transferase pi; Humans; Immunohistochemistry; Male; Neoplasm Grading; Neoplasm Proteins; Prostatic Hyperplasia; Prostatic Neoplasms

2017